Abstract
beta-Sitosterol (beta-Sit) is a dietary phytosterol with demonstrated anticancer activity against a panel of cancers, but its poor solubility in water limits its bioavailability and therapeutic efficacy. In this study, poly(lactide-co-glycolic acid) (PLGA) and block copolymers of poly(ethylene glycol)-block-poly(lactic acid) (PEG-PLA) were used to encapsulate (beta-Sit into nanoparticles with the aim of enhancing its in vitro anticancer activity. beta-Sitosterol-loaded PLGA and PEG-PLA nanoparticles (beta-Sit-PLGA and (beta-Sit-PEG-PLA) were prepared by using a simple emulsion-solvent evaporation technique. The nanoparticles were characterized for size, particle size distribution, surface charge, and encapsulation efficiency. Their cellular uptake and antiproliferative activity was evaluated against MCF-7 and MDA-MB-231 human breast cancer cells using flow cytometry and MTT assays, respectively. (beta-Sit-PLGA and (beta-Sit-PEG-PLA nanoparticles were spherical in shape with average particle sizes of 215.0 +/- 29.7 and 240.6 +/- 23.3 nm, a zeta potential of -13.8 +/- 1.61 and -23.5 +/- 0.27 mV, respectively, and with narrow size distribution. The encapsulation efficiency of (beta-Sit was 62.89 +/- 4.66 and 51.83 +/- 19.72 % in PLGA and PEG-PLA nanoparticles, respectively. In vitro release in phosphate-buffered saline (PBS) and PBS/with 0.2% Tween 20 showed an initial burst release, followed by a sustained release for 408 h. (beta-Sit-PLGA nanoparticles were generally stable in a protein-rich medium, whereas (beta-Sit-PEG-PLA nanoparticles showed a tendency to aggregate. Flow cytometry analysis (FAGS) indicated that (beta-Sit-PLGA nanoparticles were efficiently taken up by the cells in contrast to (beta-Sit-PEG-PLA nanoparticles. (beta-Sit-PLGA nanoparticles were therefore selected to evaluate antiproliferative activity. Cell viability was inhibited by up to 80% in a concentration range of 6.64-53.08 mu g/mL compared to the untreated cells. Taken together, encapsulation of beta-Sitosterol in PLGA nanoparticles is a promising strategy to enhance its anticancer activity against breast cancer cells.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Chemie und Pharmazie > Department für Pharmazie - Zentrum für Pharmaforschung |
Themengebiete: | 500 Naturwissenschaften und Mathematik > 540 Chemie |
URN: | urn:nbn:de:bvb:19-epub-67276-8 |
ISSN: | 1999-4923 |
Sprache: | Englisch |
Dokumenten ID: | 67276 |
Datum der Veröffentlichung auf Open Access LMU: | 19. Jul. 2019, 12:22 |
Letzte Änderungen: | 04. Nov. 2020, 13:49 |